For many intraoperative decisions surgeons depend on frozen section pathology, a technique developed over 150 y ago. Technical innovations that permit rapid molecular characterization of tissue samples at the time of surgery are needed. Here, using desorption electrospray ionization (DESI) MS, we rapidly detect the tumor metabolite 2-hydroxyglutarate (2-HG) from tissue sections of surgically resected gliomas, under ambient conditions and without complex or time-consuming preparation. With DESI MS, we identify isocitrate dehydrogenase 1-mutant tumors with both high sensitivity and specificity within minutes, immediately providing critical diagnostic, prognostic, and predictive information. Imaging tissue sections with DESI MS shows that the 2-HG signal overlaps with areas of tumor and that 2-HG levels correlate with tumor content, thereby indicating tumor margins. Mapping the 2-HG signal onto 3D MRI reconstructions of tumors allows the integration of molecular and radiologic information for enhanced clinical decision making. We also validate the methodology and its deployment in the operating room: We have installed a mass spectrometer in our Advanced Multimodality Image Guided Operating (AMIGO) suite and demonstrate the molecular analysis of surgical tissue during brain surgery. This work indicates that metabolite-imaging MS could transform many aspects of surgical care.
For many intraoperative decisions surgeons depend on frozen section pathology, a technique developed over 150 y ago. Technical innovations that permit rapid molecular characterization of tissue samples at the time of surgery are needed. Here, using desorption electrospray ionization (DESI) MS, we rapidly detect the tumor metabolite 2-hydroxyglutarate (2-HG) from tissue sections of surgically resected gliomas, under ambient conditions and without complex or time-consuming preparation. With DESI MS, we identify isocitrate dehydrogenase 1-mutant tumors with both high sensitivity and specificity within minutes, immediately providing critical diagnostic, prognostic, and predictive information. Imaging tissue sections with DESI MS shows that the 2-HG signal overlaps with areas of tumor and that 2-HG levels correlate with tumor content, thereby indicating tumor margins. Mapping the 2-HG signal onto 3D MRI reconstructions of tumors allows the integration of molecular and radiologic information for enhanced clinical decision making. We also validate the methodology and its deployment in the operating room: We have installed a mass spectrometer in our Advanced Multimodality Image Guided Operating (AMIGO) suite and demonstrate the molecular analysis of surgical tissue during brain surgery. This work indicates that metabolite-imaging MS could transform many aspects of surgical care. mass spectrometry imaging | oncometabolite | intrasurgical diagnosis | brain cancer | IDH1 T he microscopic review of tissue biopsies frequently remains the sole source of intraoperative diagnostic information, and many important surgical decisions such as the extent of tumor resection are based on this information. This approach is timeconsuming, requiring nearly 30 min between the moment a tissue is biopsied and the time the pathologist's interpretation is communicated back to the surgeon. Even after the report of the final pathologic diagnosis is issued days later, a lot of diagnostic, prognostic, and predictive information is left undiscovered and unexamined within the tissue. Tools that provide more immediate feedback to the surgeon and the pathologist and that also rapidly extract detailed molecular information could transform the management of care for cancer patients.
MS offers the possibility for the in-depth analysis of the proteins and lipids that comprise tissues (1, 2) . We have recently shown that desorption electrospray ionization (DESI) MS is a powerful methodology for characterizing lipids within tumor specimens (3) (4) (5) (6) . The intensity profile of lipids ionized from within tumors can be used for classifying tumors and for providing valuable prognostic information such as tumor subtype and grade. Because DESI MS is performed in ambient conditions with minimal pretreatment of the samples (7, 8) , there is the potential to provide diagnostic information rapidly within the operating room (4, 6, 9) . The ability to quickly acquire such valuable diagnostic information from lipids prompted us to determine whether we could use DESI MS to detect additional molecules of diagnostic value within tumors, such as their metabolites.
Recently, recurrent mutations have been described in the genes encoding isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in a number of tumor types including gliomas (10, 11) , intrahepatic cholangiocarcinomas (12) , acute myelogenous leukemias (13) , and chondrosarcomas (14) . These mutant enzymes have the novel property of converting isocitrate to 2-hydroxyglutarate (2-HG) (15) . This oncometabolite has pleiotropic effects on DNA methylation patterns (16) (17) (18) , on the activity of prolyl hydroxylases (19) , and on cellular differentiation and growth (20) (21) (22) . Whereas 2-HG is present in vanishingly small amounts in normal tissues, concentrations are extremely high in tumors with mutations in IDH1 and IDH2-several micromoles per gram of tumor have been reported (15) . Several groups have reported that 2-HG can be detected by magnetic resonance spectroscopy and imaging, hence providing a noninvasive imaging approach for evaluating patients (23) (24) (25) (26) (27) . Although such
Significance
The diagnosis of tumors during surgery still relies principally on an approach developed over 150 y ago: frozen section microscopy. We show that a validated molecular marker-2-hydroxyglutarate generated from isocitrate dehydrogenase 1 mutant gliomas-can be rapidly detected from tumors using a form of ambient MS that does not require sample preparation. We use the Advanced Multimodality Image Guided Operating Suite at Brigham and Women's Hospital to demonstrate that desorption electrospray ionization MS could be used to detect residual tumor that would have been left behind in the patient. The approach paves the way for the clinical testing of MS-based intraoperative monitoring of tumor metabolites, an advance that could revolutionize the care of surgical oncology patients.
imaging approaches may provide information to plan surgery and to follow the response to chemotherapeutics, applying them to guide decision making during an operation is currently impractical.
The ability to detect 2-HG intraoperatively would be particularly useful because infiltrating gliomas such as IDH1 and IDH2 mutant gliomas are difficult to visualize with conventional means, which contributes to the high prevalence of suboptimal surgical resection. Multiple studies suggest that the more residual tumor remains after surgery, the shorter the patient survival for both low-and high-grade gliomas (28) (29) (30) (31) (32) . Detecting infiltrating glioma cells by microscopic review is challenging on well-prepared H&E-stained permanent sections, and even more so on H&E-stained frozen sections, which frequently harbor processing artifacts. Thus, 2-HG detection could help to define surgical margins, thereby allowing for more complete resection and for longer survival (31, 32) . Moreover, directing patients toward appropriate clinical trials for targeted therapeutics (33) would be facilitated by more rapid molecular categorization of tumors.
Here, we show that 2-HG can be rapidly detected from glioma samples using DESI MS under ambient conditions, without complex tissue preparation and during surgery, allowing rapid molecular characterization and providing information that is unattainable by standard histopathology techniques. We also present the first implementation, to our knowledge, of MS within an operating room for the molecular characterization of tissue as part of an image-guided therapy program. We cross-validate our findings using standard pathology techniques. Measuring specific metabolites in tumor tissues with precise spatial distribution and under ambient conditions provides a new paradigm for intraoperative surgical decision making, rapid diagnosis, and patient care management.
Results
Identification of 2-HG with DESI MS. To determine the conditions for detecting 2-HG from glioma frozen tissue sections by DESI MS, we first recorded the negative ion mode mass spectra from two glioma samples: an oligodendroglioma with mutated IDH1 (encoding the amino acid change R132H) and a glioblastoma with wild-type IDH1. The product of mutant IDH1, 2-HG, is a small organic acid containing two carboxylic acid functional groups in its structure. In the negative ion mode, the deprotonated form of 2-HG should be detected at an m/z of 147.03 (C 5 H 7 O 5 − ). Together with the rich diagnostic lipid information commonly observed from gliomas by DESI MS in the mass range m/z 100-1,000, we detected a significant peak at m/z 147 in an IDH1 mutated sample (Fig. 1A) , but not in an IDH1 wild-type sample (Fig. 1B) .
We used tandem MS analysis (MS 2 ) with a linear ion trap mass spectrometer to characterize the signal at m/z 147 ( Fig. S1 and Fig. 1 C-F) . In an oligodendroglioma with the IDH1 R132H mutation, the main fragment ion generated from m/z 147 was m/z 129, which corresponds to loss of a water molecule from 2-HG (Fig. 1C) . Further characterization of m/z 129 with an additional stage of MS analysis (MS 3 ) yielded two additional fragment ions at m/z 101 and m/z 85, corresponding to neutral losses of CO and CO 2 , respectively (Fig. 1D) . We obtained identical MS 2 and MS 3 fragmentation patterns when we subjected purified L-α-hydroxyglutaric acid to tandem MS experiments ( Fig. 1 E and F) . A purified standard of the wild-type IDH metabolite alpha-ketoglutarate was detected at m/z 145, and MS 2 and MS 3 fragmentation patterns yielded peaks at m/z 101 and at m/z 73 and m/z 57, respectively (Fig. S2) . We further characterized the 2-HG peaks using a high-resolution and high-mass accuracy linear trap quadrupole (LTQ) Orbitrap mass spectrometer (Fig. S3) . DESI mass spectra from an IDH1 R132H mutant sample showed a prominent peak at m/z 147.0299 in the negative ion mode, which matched the molecular formula of the deprotonated form of 2-HG (C 5 H 7 O 5 − ) with a mass accuracy of 0.3 ppm. In all, these results confirm the ability to reliably and rapidly detect 2-HG from human glioma tissue sections with DESI MS.
Levels of 2-HG Correlate with Mutational Status and Tumor Cell
Content. We next monitored the levels of 2-HG using DESI MS in a panel of 35 human glioma specimens (Table S1 ) including primary and recurrent oligodendrogliomas, oligoastrocytomas, and astrocytomas of different grades (3). We first characterized the samples using a clinically validated antibody that selectively recognizes the R132H mutant epitope and not the wild-type epitope from IDH1 (34) ( Table S1 ). Twenty-one of the 35 samples had the R132H mutation. We then measured 2-HG levels in these samples directly from frozen tissue sections using a linear ion trap LTQ DESI. In some samples we detected a peak at m/z 147 and assigned it to 2-HG by MS 2 analysis, thereby providing strong independent evidence that these samples were mutated for one of the IDH genes. To account for the variability in desorption and ionization efficiency throughout the tissue and between samples, we normalized the 2-HG signal to the combined intensity of the 40 most abundant lipid species that were detected during each data acquisition (Table S1 and Supporting Information). In all of the 21 samples with the IDH1 R132H mutation, we clearly detected 2-HG with a limit of detection estimated to be 3 μmol 2-HG/g of tissue (Fig. S4) , which is below the lowest concentration of 2-HG in tissue in IDH1 mutant human gliomas as measured by HPLC-MS analysis (23) .
We also observed a correlation between the concentration of tumor cells and the intensity of the 2-HG signal: Samples with low concentrations of tumor cells (<50%) had lower 2-HG levels, whereas samples with high concentrations of tumor cells (>50%) had higher 2-HG levels (Fig. S5) . Although the sample set of high-density tumors (≥80% tumor cells) is relatively small, we noted that glioblastomas with mutant IDH1 generally had lower levels of 2-HG than oligodendrogliomas (Fig. S5) .
Interestingly, in two of the samples (G33 and G28) that were negative for the IDH1 R132H mutation by immunohistochemical staining ( Fig. 2A) , we detected 2-HG signal by DESI MS (Fig.  2B) . The signal from both samples was confirmed to be from 2-HG by MS 2 analysis. Because other mutations in IDH1 or IDH2 can lead to 2-HG accumulation (35-37), we performed targeted sequencing (38) for all of the major mutations in IDH1 and IDH2 that have been described in gliomas (39) . This analysis revealed that both samples G33 and G28 harbored a less common but previously described IDH1 mutation that leads to substitution of the amino acid arginine with glycine at position 132 (R132G) (Fig. 2C) . These results provide a clear example of how detecting 2-HG with DESI MS allows rapid and accurate determination of IDH1 status in human gliomas. Whereas the diagnostic antibody only recognizes one of the many IDH1 mutants (37), DESI MS captures the presence of 2-HG independent of the underlying genetic mutation in IDH1. Notably, our results show that DESI MS can detect 2-HG with very high sensitivity and specificity: We detected 2-HG signal in all cases with mutant IDH1 (even when the tumor concentration was as low as 5%) and did not detect 2-HG signal in any of the cases with wild-type IDH1.
DESI MS 2D Imaging of 2-HG in Glioma Sections Delineates Tumor
Margins. To further validate DESI MS as a tool for monitoring 2-HG levels, we turned to 2D DESI MS imaging to study the spatial distribution of molecules across a tissue section (40) . DESI MS imaging has recently been shown not to destroy a sample as it is being analyzed when a histologically compatible solvent system is used (40) . This relative preservation allows the same tissue section to be stained with H&E following DESI MS data acquisition, and the spatial molecular information derived from DESI MS can then be overlaid onto the optical image of the tissue (40) . As such, this approach provides a powerful way to correlate 2-HG levels with histopathology and, importantly, to validate the DESI MS observations. As a control, we acquired 2D DESI MS data from frozen sections of human glioblastoma orthotopic xenograft models that had been implanted into the brains of immunocompromised mice (Fig. S6) . A signal for 2-HG was not detected from xenografts of a glioblastoma cell line (BT329) that has wild-type IDH1 (Fig. S6A) . Strikingly, however, a strong signal for 2-HG was found throughout the tissue section of the mouse brain that was diffusely infiltrated by a glioblastoma xenograft (BT116) that has the IDH1 R132H mutation (Fig. S6B) , as was similarly observed in an IDH1 R132H mutated oligodendroglioma xenograft model by liquid extraction surface analysis nano electrospray ionization-MS imaging (41) .
We next turned to tissue sections of human glioma specimens that had been surgically resected. Using 2D DESI MS with both an LTQ ion trap (Thermo Fisher Scientific) and an amaZon Speed ion trap (Bruker Daltonics), we observed accumulation of 2-HG within a densely cellular glioblastoma with mutated IDH1 (Fig. S7 ). 2-HG was absent in an area of hemorrhage abutting the tumor (Fig. S7) . In tissue specimens from two additional glioma resections, we identified areas that contained regions of tumor as well as regions of brain with only scattered infiltrating glioma cells (i.e., the margin of the tumor). DESI MS revealed strong 2-HG signals in the cellular portions of these samples but weaker signals in the portions of brain with scattered infiltrating tumor cells. By validating our DESI MS results directly with tissue histopathology, we show that monitoring 2-HG levels with DESI MS can help to readily discriminate tissue with dense tumor from tissue with only scattered tumor cells. Such discriminatory capacity can help define tumor margins.
Three-Dimensional Mapping of 2-HG onto MRI Tumor Reconstructions.
MRI information is critical for planning neurosurgical procedures. During the surgery, neuronavigation systems allow the neurosurgeon to register the position of surgical instruments with preoperative plans (i.e., confirming where the tools are relative to the imaging findings). Surgeons can therefore digitally mark the site of a biopsy relative to the tumor in the MRI. We resected two IDH1 mutated gliomas in this manner, using 3D mapping, marking the positions of multiple biopsies in each case. In both cases, we measured the 2-HG content of each stereotactic specimen and normalized to its lipid signals (see Materials and Methods and Supporting Information for details). We then correlated this information with the tumor cell content of each stereotactic specimen, as determined by review of both H&E and immunostains for IDH1 R132H.
In the resection of an oligodendroglioma (Fig. 3) , we identified strong 2-HG signals in the sample (D3) taken from the center of the tumor mass (Fig. 3A) . This sample was composed of dense tumor ( Fig. 3 B and C) . Biopsies from the margins of the radiographic mass (e.g., D10, Fig. 3 B and D) contained low concentrations of infiltrating glioma cells (Fig. 3D ). In such samples we detected low levels of 2-HG (Fig. 3A) . Consistent with our prior findings on a large panel of glioma specimens (Fig.  S4 and Table S1) , these stereotactic samples demonstrate that the normalized level of 2-HG correlates with the tumor cell concentration and can help define samples that are at the infiltrating border of the tumor.
We performed a second surgical resection (Fig. S8 ) in the Advanced Multimodality Image Guided Operating (AMIGO) suite (42) at Brigham and Women's Hospital that is a part of the National Center for Image-Guided Therapy. In this advanced surgical and interventional environment, MRI can be performed during the operation to see whether additional tumor remains in situ. This residual tumor can then be resected before the procedure is completed.
An oligoastrocytoma was resected in this second case. We digitally registered the location of multiple biopsy pieces to the preoperative MRI and measured 2-HG levels in each of them (Fig. S8A) . The highest levels of 2-HG were detected in specimens that were taken from the center of the tumor mass, which proved to be dense cellular tumor (Fig. S8B) . We took an intraoperative MRI of the patient's brain once it seemed that the entire tumor had been removed (i.e., following an apparent gross total resection). The T2-weighted intraoperative image revealed a region that was of concern for residual tumor, and surgery for Immunohistochemistry using an IDH1 R132H point mutation-specific antibody on formalin-fixed and paraffin-embedded sections from glioma samples (G23, G33, and G28). (Scale bar, 100 μm.) (B) Negative ion mode DESI mass spectra obtained using a linear ion trap mass spectrometer for samples G33 and G28 that are negative for IDH1 R132H mutant immunohistochemistry. (C) Targeted mutational profiling using SNaPshot analysis on nucleic acids extracted from gliobastoma archival specimens (G33 and G28) run in parallel with a normal genomic DNA control, as indicated. The arrows point to the IDH1 R132G (c.394C > G) mutant allele identified in both tumor samples. The assayed loci were as follows: (1) more complete resection was continued based on the MRI finding (Fig. S8C , outlined in green in the inset). Because the areas that were of concern for residual tumor were close (just anterior) to the premotor cortex, we carefully sampled them to preserve the patient's motor function. We digitally registered two additional specimens to the intraoperative MR image, samples S60 and S61. We detected an equivocal 2-HG signal from one sample (S61) but robust 2-HG signal from the other (S60) (Fig.  S8C ). Microscopic review of the HE and IDH1 R132H immunostained sections revealed only scattered tumor cells in sample S61 (<5% tumor nuclei by H&E frozen section analysis) but numerous tumor cells in sample S60 (∼20% tumor by H&E frozen section analysis) (Fig. S8D) . This clinical example demonstrates a scenario where surveying the resection cavity with DESI MS could eventually identify areas of residual tumor without interrupting surgery for intraoperative MRI.
Real-Time Intraoperative Detection of 2-HG. Successfully implementing DESI MS in the operative setting requires that we demonstrate the feasibility of immediately detecting 2-HG in the operating room from tissue biopsies. In Fig. 4A we outline the standard work flow for brain surgery in the AMIGO suite using current methodologies and the increased sampling that is possible with DESI MS. To test our ability to measure 2-HG in this setting, we installed a complete DESI MS system in the AMIGO suite and monitored 2-HG levels from multiple biopsies as they were resected from two patients.
In one case, a patient had had an oligoastrocytoma [World Health Organization (WHO) grade II] resected 6 y earlier. Upon recurrence of the tumor, we reoperated on the patient in our AMIGO suite. Interestingly, subsequent IDH1 molecular testing showed that the tumor lacked the R132H mutation by immunohistochemistry (IHC) testing (Fig. S9A) but had an R132C mutation as detected by targeted sequencing (Fig. S9B) . This information was unknown to us at the time of surgery. We sampled the tumor biopsies in two ways: We applied miniscule amounts of biopsy material to a standard glass slide either with a swab (the ones used for swab cultures) or by smearing a tiny tissue fragment between two glass slides (i.e., a standard smear preparation) (Fig. S9C) . Within minutes, from both preparations, we clearly detected a peak that corresponded to 2-HG (m/z 147.0) (e.g., data from sample S72 are shown in Fig. 4B ) and confirmed this with tandem MS (Fig. S9D) . After the operation, in our laboratory outside of the AMIGO suite, we confirmed the presence of 2-HG in these biopsies with DESI MS imaging in samples taken from the center of the tumor (S73) as well as those taken from along the tumor edge (S71 and S74) (Fig. 4C) . Similarly, in a resection of a recurrent anaplastic oligoastrocytoma (WHO grade III) in our AMIGO suite we rapidly detected 2-HG on smear preparations from multiple biopsies (Fig. S10) . IHC performed days later as part of the routine clinical analysis confirmed the presence of the IDH1 R123H mutation.
Discussion
We have previously demonstrated that many tumor types can be discriminated based on their lipid profile. Here, using gliomas with IDH1 mutations as an example, we show that a single metabolite, which was monitored during surgery with ambient MS techniques, rapidly provides highly relevant information: tumor classification (i.e., 2-HG-expressing CNS tumors are nearly always gliomas), genotype information (i.e., 2-HG-expressing tumors carry mutations in IDH1 or IDH2), and prognostic information (i.e., 2-HG-expressing tumors have a more favorable outcome) (43-46)-all with excellent sensitivity and specificity.
Because about 80% of grade II and grade III gliomas as well as the majority of secondary glioblastomas contain IDH1 or IDH2 mutations (43), monitoring 2-HG with intraoperative MS could conceivably become routinely used for surgeries of primary brain tumors, first to classify the tumor and then, if 2-HG is present, to guide optimal resection. In tumors lacking 2-HG, surgical guidance would require monitoring lipid signatures or other metabolites. Presumably, the approach we describe here could be applicable for the resection of all 2-HG-producing tumors including chondrosarcoma and cholangiocarcinoma. Used in conjunction with lipid profiles, a detailed understanding of the tumor could be generated rapidly.
Unlike more time-consuming HPLC MS approaches that are standard for quantifying 2-HG, ambient MS techniques enable rapid data acquisition and are therefore compatible with the rigorous time constraints of surgery. Because of this, the approach described in our work can provide the intraoperative guidance needed to guide the iterative process of optimizing a resection-discriminating tumor from normal brain tissuea distinction that is of utmost importance in neurosurgery for improving patient outcomes [increased survival (29, 31, 32) and decreased morbidity (47) ]. Note that the typical spatial resolution of DESI MS is ∼200 μm (3, 7), which is ample for evaluating surgical biopsies, which are often 2 mm or more in size.
Although MRI is an important intraoperative tool (48) it does have limitations. MRI is an indirect measure of the presence of a tumor; it does not definitively reveal the type of tumor that is being operated on and can sometimes not discriminate tumor from reactive adjacent tissue; each intraoperative MRI scan requires 1 h or longer to perform and interpret; MRI is not an iterative process (i.e., generally only one scan can be performed during a procedure); and the surgeon needs to extrapolate what is learned from the MRI to judge how much more tissue needs to be removed (without being able to ask specifically and directly whether the exact tissue area in question in the surgical field is truly tumor tissue). Moreover, deformation of brain structures occurring following craniotomy (i.e., "brain shift") renders preoperative images inaccurate, as seen for the mapping of sample biopsy sites for S92 and S95 in Fig. S9B . Importantly, performing an MRI is a major interruption to the surgical procedure. Moreover, each operating room that contains an MRI machine costs over $10 million, so intraoperative MRIs are found in only the most advanced operating rooms and access to these important technologies is somewhat restricted for many surgeons and patients alike. DESI-MS platforms could be implemented in essentially any operating room facility at a very small fraction of the costs. It is clear how characterizing 2-HG with DESI MS could play an important role in neurosurgery.
Other metabolites such as succinate and fumarate, which accumulate in specific tumor types (49) , may similarly prove to be valuable metabolite markers for guiding surgery with MS approaches. As metabolomic discovery efforts intensify, the cadre of useful metabolite markers will expand significantly. This will undoubtedly increase the breadth of applications and the diagnostic utility of MS-based approaches that could use DESI technologies or other ambient ionization methods (2, 50-52). Fluidly assessing molecular information, in a rapid timeframe, should allow more accurate determination of tumor margins informed by molecular cues (i.e., "molecular margins"), enhancing the likelihood of achieving optimal tumor resection. The low tissue requirements for our methods also raise the possibility of detection in fine-needle aspirations, core-needle biopsies, or bonemarrow biopsies of a wide range of tumor types in both surgical and nonsurgical settings, and some preliminary data supporting this claim are available (53, 54) .
To date, surgery remains the first and most important treatment modality for patients suffering from brain tumors. Because of the potential that we describe here, metabolite-imaging MS is a new tool with broad and powerful clinical and research applications that could transform the surgical care of patients with brain and other solid tumors. 
Materials and Methods
Tissue Samples. The tissue samples used in this study were obtained from the Brigham and Women's Hospital/Dana-Farber Cancer Institute Neurooncology Program Biorepository collection as previously described (3) or from stereotactic surgical cases as described in Fig. 4 and Fig. S10 . For additional details see Supporting Information. Genetic analysis was performed as described in Supporting Information.
Tissues were sectioned and immunostained as previously described (3). For details see Supporting Information.
Identification of 2-HG by DESI MS. To determine whether 2-HG could be detected directly from glioma tissue sections by DESI MS imaging, we analyzed human glioma samples by DESI MS in the negative ion mode using either an LTQ ion trap (Thermo Fisher Scientific) or an amaZon speed ion trap (Bruker Daltonics). For additional details see Supporting Information.
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Extended Description of Fig. 4A Intraoperative MS allows for significant advances in the frequency of intraoperative tissue sampling as well as improvements in time from tissue sampling to availability of tissue analysis that can influence intraoperative surgical decision making. The schematic in Fig. 4A shows standard-of-care practices including pre-and postoperative tests (including preoperative planning MRI, permanent surgical tumor pathology analysis, and genomic analysis of intraoperative tumor tissue samples). Also demonstrated is the intraoperative (i.e., surgical) workflow, including intraoperative MRI, frozen sectioning, and MS tissue analysis. All intraoperative time periods are drawn to scale according to the time required for each test. Currently, on a research basis, intraoperative MS analysis is typically completed within 2 min, whereas frozen section analysis is completed in 20-30 min and intraoperative MRI requires at least 60 min. The time course of each intraoperative analytical measurement is measured from the time that the tissue sample is taken from the brain of the patient (or the time that the patient is readied for MRI scanning) until information from the test can returned to the surgeon to help guide the remainder of the surgery. The MS analysis time points denote an example of the timing and frequency of representative sampling periods during an operation. MS time periods (hash-marked orange rectangles) connote that MS is not yet standard of care and is a research test.
Tissue Samples
All samples were obtained and analyzed under Institutional Review Board protocols approved at Brigham and Women's Hospital (BWH) and Dana-Farber Cancer Institute. Informed written consent was obtained by neurosurgeons at BWH. Tumors were rereviewed and classified in accordance with the World Health Organization classification system by board-certified neuropathologists (S.S., K.L.L.). Resections of brain tumor lesions were performed using neuronavigation, with stereotactic mapping and spatial registering of biopsies performed. Threedimensional reconstructions of the tumor from MRI imaging data were achieved with the 3D Slicer software package. Gliobastoma xenografts BT116 and BT329 were derived from surgical resection material acquired from patients undergoing neurosurgery at the BWH on an Institutional Review Board-approved protocol. Briefly, tumor resection samples were enzymatically and mechanically dissociated using the MACS Brain Tumor Dissociation Kit (Miltenyi Biotech) to generate single-cell suspensions. Intracranial xenografts were generated by injecting 100,000 cells in the right striatum of SCID mice (IcrTac: ICR-Prkdcscid; Charles River Labs) and aged under standard conditions until onset of neurological symptoms. Killed xenografts were perfused by intracardiac injection of 4% paraformaldehyde and processed by standard methods for paraffin embedding.
Histopathology and Immunohistochemistry. In addition to banked snap-frozen samples, all cases had tissue samples that were formalin-fixed and paraffin-embedded (FFPE). Sections of FFPE tissue were stained with an anti-isocitrate dehydrogenase 1 (IDH1)-R132H antibody (clone HMab-1 from EMD Millipore) as previously described. H&E-stained serial tissue sections were scanned using Mirax Micro 4SL telepathology system from Zeiss to generate digital optical images. Tumor content was evaluated by board-certified neuropathologists (S.S. and K.L.L.) through examination of H&E-stained tissue sections and IDH1 R132H-stained sections.
Identification of 2-Hydroxyglutarate by Desorption Electrospray Ionization MS. The IDH1 status of each specimen was initially evaluated by immunohistochemistry (IHC) of a piece of FFPE tissue. For stereotactic cases, all biopsies were less than 0.4 cm and these specimens were divided into two [one portion was frozen for desorption electrospray ionization (DESI) MS studies and the other was processed for FFPE; the latter was used for IDH1 IHC].
To determine whether 2-hydroxyglutarate (2-HG) could be detected directly from glioma tissue sections by DESI MS imaging, we analyzed human glioma samples by DESI MS in the negative ion mode using either a linear trap quadrupole (LTQ) ion trap (Thermo Fisher Scientific) or an amaZon speed ion trap (Bruker Daltonics). The solvent used in these experiments consisted of either MeOH:H 2 O (1:1) or ACN:DMF (1:1) with a mass from m/z 100-1,100. All experiments involving the amaZon speed ion trap were carried out using a 5-kV spray voltage, 130 psi nebulizing gas (N 2 ), and a flow rate of 0.7 μL/min.
Tandem MS analysis was used for identification of the molecular species at m/z 147.2. Further characterization was performed by tandem MS with an additional stage of MS analysis (MS 3 ). The standard compound L-α-hydroxyglutaric acid disodium salt (Sigma-Aldrich Inc.) was subjected to tandem MS experiments under the same conditions. Confirmation experiments were performed using a high-resolution LTQ Orbitrap mass spectrometer (Thermo Fisher Scientific). Further analysis was then conducted with the amaZon speed ion trap. For this instrument, the 2-HG signal was located at m/z 146.9 and was assigned using a mouse brain that contained a large tumor with the 2-HG mutation. Tandem MS and MS 3 experiments were conducted on this peak to confirm its identity and found to be identical to the fragmentation pattern obtained with the LTQ instrument. Imaging of another mouse brain that had another tumor without the 2-HG mutation did not show this peak.
A description of the samples used in this initial testing stage of this study (analyzed with the LTQ ion trap) is shown in Table S1 . Negative ion mode DESI MS mass spectra of samples G23 and G31 are shown in Fig. 1 , using MeOH:H 2 O (1:1) as the solvent system. In total, we analyzed 35 human glioma samples presented in Table S1 , including oligodendrogliomas, astrocytomas, and oligoastrocytomas of different grades and varying tumor cell concentrations, using both ion trap mass spectrometers. Note that because tissue analysis by DESI MS is performed without sample preparation but directly on tissue section, standard quantification of 2-HG as commonly performed with timeconsuming HPLC-MS protocols is not possible. One means by which relative levels of a certain molecule can be calculated is by normalizing its signal to a reference signal or set of signals obtained from the sample. In our study, the total abundance of 2-HG signal at m/z 147 was normalized to the sum of total abundances of the most abundant lipid species detected from the glioma samples by DESI MS. The mass spectra were exported as nominal mass from Xcalibur software (Thermo Fisher Scientific), and the absolute intensities of the 40 most abundant lipid species within m/z 700-1,000, which had been previously identified by tandem MS, were summed. Noise or background peaks within that m/z range were not considered. Normalization was then accomplished by dividing the total intensity of 147 by the summed intensities of the lipid species. Note that because a small contribution of background signal at the same m/z 147 was present in DESI mass spectra, MS 2 was performed for all samples to confirm the presence of 2-HG. This was especially important in some IDH1 mutant samples with low tumor cell concentrations and therefore much lower abundances of 2-HG in DESI mass spectrum. If the MS 2 fragmentation pattern matched that of authentic 2-HG, the sample was determined to be IDH1-mutated. Discrepancies in the fragmentation pattern or absence of detectable levels of m/z 147 were interpreted as IDH wild type by MS analysis. Results for DESI MS analysis were obtained using two solvent systems. Note that although the solvent system DMF:ACN (1:1) favored relative abundances of low m/z ions compared with MeOH:H 2 O, similar trends in 2-HG were observed for both solvents. Interestingly, the ratio of m/z 147 to the sum of lipid species correlated with the tumor cell concentration determined for the sample by histopathological evaluation of serial tissue section, providing a direct measure of the 2-HG levels in tissue. Most samples that were negative for IDH1 mutation as determined by IHC did not present 2-HG in the DESI MS mass spectra, even if the sample presented high tumor cell concentration, as confirmed by tandem MS analysis (with the exception of two samples as noted in the text).
One of the challenges in the analysis was to determine IDH1 status by DESI MS detection of 2-HG in samples with low tumor cell concentration from full mass spectral data. For these samples, low detectable values of m/z 147 could be initially assumed as an indication of IDH negative mutation. Nevertheless, MS 2 and MS 3 of m/z 147 enabled IDH mutation status confirmation for these samples, despite the low tumor cell concentration (as low as ∼5% of tumor). DESI MS imaging was performed for a few of the samples analyzed to evaluate the distribution of 2-HG and other diagnostic lipid species compared with tumor cell distribution in tissue.
Genetic Analysis
Archival surgical specimens were reviewed by a pathologist (S.S.) to select the most appropriate tumor-enriched area for analysis. Total nucleic acid was extracted from FFPE tumor tissue obtained by manual macrodissection, followed by extraction using a modified FormaPure System (Agencourt Bioscience Corporation). Targeted mutational analysis (SNaPshot) of a panel of cancer genes that included IDH1 and IDH2 was performed.
The primers listed below were used for targeted mutation analysis at codon R132 in IDH1 (nucleotide positions c.394 and c.395) and at codons R140 and R172 in IDH2 (nucleotide positions c.418, c.419, c.514 and c.515). PCR primers: IDH1 exon 4, 5′-ACGTTGGATGGGCTTGTGAGTGGATGGGTA-3′ (forward) and 5′-ACGTTGGATGGCAAAATCACATTATTGCCAAC-3′ (reverse); IDH2 exon 4a (to probe codon R140), 5′-ACGTTG-GATGGCTGCAGTGGGACCACTATT-3′ (forward), and 5′-AC-GTTGGATGTGGGATGTTTTTGCAGATGA-3′ (reverse); and IDH2 exon 4b (to probe codon R172), 5′-ACGTTGGATGAA-CATCCCACGCCTAGTCC-3′ (forward), and 5′-ACGTTGGAT-GCAGTGGATCCCCTCTCCAC-3′ (reverse).
Extension primers: IDH1.394 extR 5′-GACTGACTGGAC-TGACTGACTGACTGACTGGACTGACTGACTGAGATC-CCCATAAGCATGAC-3′, IDH1.395 extR 5′-TGATCCCCAT-AAGCATGA-3′, IDH2.418 extR 5′-GACTGACTGACTGAC-TGACTGACTGACTGACTGACTGGACTGACTGACTGAC-TGCCCCCAGGATGTTCC-3′, IDH2.419 extF 5′-GACTGA-CTGGACTGACTGACTGACTGAGTCCCAATGGAACTAT-CC-3′, IDH2.514 extF 5′-GACTGACTGACTGACTGACTGA-CTGACTGGACTGACTGACTGACTGACTGGACTGACT-GACCCATCACCATTGGC-3′, and IDH2.515 extR 5′-GA-CTGACTGACTGACTGACTGACTGACTGACTGACTGG-ACTGACTGACTGACTGACTGGACTGACTGAGCCATGG-GCGTGC-3′. Note that the correlation in both plots is significantly improved if the concentration range is limited to 100 μmol/g. The limit of detection was estimated to be 3 μmol 2-HG/g of tissue. Table 1 for sample details). Blue bars, low tumor cell concentration; red bars, high tumor cell concentration. A, astrocytomas; O, oligodendrogliomas; and OA, oligoastrocytomas. Fig. S6 . Two-dimensional DESI MS ion images of human glioma cell xenografts in immunocompromised mice. (A) Negative ion mode 2D DESI MS images of human glioblastoma xenograft (BT329) that has wild-type IDH1 and (B) human glioblastoma xenograft (BT116) that has an IDH1 R132H mutation. The left panel is an ion map demonstrating the relative signal intensity of peak m/z 146.9, which was confirmed to be 2-HG by tandem MS analysis (MS 2 and MS 3 ). Relative signal intensity (0-100%) is plotted for each specimen using a color scale. Low magnification and high magnification light microscopy images of H&E-stained sections are shown, and IDH1 R132H point mutation specific antibody staining on the far-right panel. (Scale bar, 100 μm.) . MS data for sample G30 was acquired using an LTQ ion trap (Thermo Fisher Scientific). Relative signal intensity (0-100%) is plotted for each specimen using a color scale. Low magnification light microscopy images of H&E-stained sections show the tissue outline. The red boxed area indicates a region of higher tumor cell concentration. The black boxed area indicates blood. 
